You can tell from action of the stock. It was very close miss in one aspect but quite good on others. According to conference call, even the very close miss on breast cancer, is much better than any drug out there. I think they can get approval and will sell well until something better comes along.
warning label in this case is actually good thing, really, go study this thing a little bit. This increases iron, which paitience need, but warning says be careful adding another Iron medication that you would normally do, you may not need it.
what in the world are you talking about? they are not even same drug. Auryxia is phosphate binders with iron replacement benefit. Auryxia sales in Japan are doing very well and growing fast, I don't see why it would be different here. I think once it gets going, sales will accelerate.
This is a trust that has no expenses, it receives royalty on revenues. So even if operators lose money, we receive net dollars based on revenue. having no expense, and no debt, there is no chance of demise. we can only make money, we can't lose, a sweet deal.
There are 2 positives happening right now, first the Ultradeep's first well at 75 million cubic feet / day is a very nice well, and there is a lot more on the way. Second, the water oil separation processing bottleneck which has held back production should be resolved by now. So, baby load up on this going back to 20s soon.
Wow, this is going to run to $30, to $40 range soon. Huge short, and news getting better and better and very few float. This will start moving in Dollars instead of cents soon
They don't have a new drug, they have a portable pump for administering the existing drug. I will see if I could short it. The word Parkingson has got people excited.
People are spooked by the fact that UPL has a high debt, but they are wrong here. UPL has only about $150 million of interest expenses a year on revenue of over $1.2 Billion. There is no material debt coming due for the next 2 years, I think about $200 Million, with plenty of bank credit line to take care of them. Ultra's revenue is over 75% from gas, where gas price has nowhere near impacted as has oil. What is interesting here is that expected reduction in shale oil production, will reduce associated gas production and will actually benefit gas prices. UPL is at the top of the low cost gas producers, and will survive and benefit greatly from this healthy shakeout, with resulting much healthier business later on. So buckle up, don't sell this baby, in fact take advantage and buy more here.
I do not think the run is because of Ebola, but it is about the good news coming on pancreatic cancer drug doing well enough to stop the trail, and give the drug to everyone on the trail.
And then comes in the royalty payments. This stock is worth well over $80. Grossly undervalued. I think the Ebola crowd are selling, once that is done, this stock will shoot up crazy, it has a lot of short to boot. Short squeeze here she comes.
UPL is by far benefits from higher gas prices. A major part of uncontrolled gas production has been the gas that has been produced as a byproduct of the oil drilling. With less oil drilling, nat gas prices should go higher. A silver lining in dropping oil price for UPL. UPL has already said that their oil Acquisition will be nicely profitable at $80 oil price.
My opinion only, but I think this management thought they were smarter than Exxon, bought their depleted wells, then went on to buy even more mature fields on another cash transaction in the gulf, saddling the company with debt. Come to find out that depleted wells are producing water instead of oil, don't have enough capacity to separate the oil from water, the oil prices dropping like mad. I have a very bad feeling about this company. I bought into this company with the hope that their ultra deep venture with McMoran will bear fruit, but that is not happening either. I still own some shares, can anyone here give a reason that I should hold on. I desperately want to be wrong, but am I,? anyone?
Who do you want to listen to, the man who has written a book on investment, which is out of print and sells for over $2000 a copy, and has amassed $billion of by investing or Adam Fewer Stein